Literature DB >> 3610682

[Allergic reaction in therapy with naftidrofuryl (Dusodril). A case report].

R G Matschke.   

Abstract

There are many drugs marketed for the purpose of altering vascular blood flow in various regions, especially of the central nervous system and in peripheral arterial insufficiency. More than 50 different methods are described for the treatment of sudden deafness. Considerations of the therapy of sudden deafness are influenced by the fact that the cause of the disease is unknown. The dysfunction of the hair-cells of the organ of CORTI is thought to be caused by a deficit of oxygen due to disorders of micro-circulation in the inner ear. The infusion of vaso-active drugs in the early state of disease can lead to a remarkable improvement of hearing whereas the prospect of improvement without treatment remains uncertain. Nevertheless it may be difficult to distinguish the beneficial effects of vasodilator agents from spontaneous improvement. Naftidrofuryl oxalate (dusodril) has been in use for many years and proved its therapeutic value in many studies. It is regarded as non-toxic and is used extensively in Europe. Side effects are only reported rarely, and include decrease of cerebral blood flow, abdominal distension, diarrhoea, oesophageal ulceration, epileptic seizures, aphasia, disturbances of consciousness, hypotension, hypertensive crisis, vertigo and dizziness, depression of cardiac conduction, thrombophlebitis, and allergy. This case report of allergic reaction in a young female patient demonstrates that the intravenous application of this drug may lead to severe complications.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3610682

Source DB:  PubMed          Journal:  HNO        ISSN: 0017-6192            Impact factor:   1.284


  1 in total

1.  Reversible global aphasia as a side effect of quetiapine: a case report and literature review.

Authors:  Ching-Fang Chien; Poyin Huang; Sun-Wung Hsieh
Journal:  Neuropsychiatr Dis Treat       Date:  2017-08-28       Impact factor: 2.570

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.